MIRAE SKIN

Manufacturer: HUMAN AND NATURE
Effective date: 2018-12-19
Label type: HUMAN OTC DRUG LABEL
Version: 4
Source: full-release
Hydrated at: 2026-05-31 22:57:45

Label at a glance#

ProductMIRAE SKIN

Active ingredientWITCH HAZEL

Label structure8 sections

Indications and uses

Indication and usage: 1. After face washing and bathing, to remove moisture. 2. Firstly fine bubbles out with SKIN soap and put them on the entire face with soft massage. 3. When bubbles under the skin was left little you should sum up with foundation makeup.

Dosage and administration

Dosage and administration: At least once in 24 hours to use.

Label contents#

Full prescribing information#

Active Ingredient

OTC - ACTIVE INGREDIENT SECTION

Active ingredient: WITCH HAZEL 0.1%

Inactive Ingredients

INACTIVE INGREDIENT SECTION

Inactive ingredients:
Aqua (Purified Water), Saponin, Linoleic Acid, Sodium Hydroxide, Carbohydrate, Quercetin, Flavonoid, Oleic Acid, Kaolin, Sodium, Vitamin B1, dietary fiber, Vitamin B2, Protein, Lauric Acid, Zinc Oxide, Ascorbic Acid, Allantoin, Myristic Acid, Vitamin E, Caprylic Acid, Decanoil Acetaldehyde, Palmitic Acid, Colloidal Oatmeal

Purpose

OTC - PURPOSE SECTION

Purpose: Atopy, Dry Skin, Moisture, Itching, Pimple and Skin-Care

Warnings

WARNINGS SECTION

Warnings:
Due to the nature of natural soap this products can be dissolved in water and moisture to escape, so please keep note.
Because production process have all been accomplished by hand-made, Net weights and colors may be different from others slightly.

Keep out of reach of children

OTC - KEEP OUT OF REACH OF CHILDREN SECTION

Keep out of reach of children:
Keep out of reach of babies and children.

Uses

INDICATIONS & USAGE SECTION

Indication and usage:
1. After face washing and bathing, to remove moisture.
2. Firstly fine bubbles out with SKIN soap and put them on the entire face with soft massage.
3. When bubbles under the skin was left little you should sum up with foundation makeup.

Directions

DOSAGE & ADMINISTRATION SECTION

Dosage and administration:
At least once in 24 hours to use.

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Image of carton

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUI	RxNorm string	TTY	SPL version
1151061	witch hazel 0.1 % Medicated Bar Soap	PSN	4
1151061	witch hazel 0.001 MG/MG Medicated Bar Soap	SCD	4
1151061	witch hazel 0.1 % Medicated Bar Soap	SY	4

DailyMed Product Concepts#

Product concept, Relation, Version table
Product concept	Relation	Version	Effective
3c386306-c48a-413e-bb69-70cb268496f3	Product name	1	20210727

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDC	Effective	Action	Document	Indexing SPL	Related label
43071-100-01	2021-01-29	C162847	48780-1	ba0f9c33-2de7-a910-e053-dadaa90a0b85	Drug Facts

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDC	Product	Description	Form	Quantity	Strength	SPL version
43071-100-01	MIRAE SKIN	150 g in 1 CARTON	SOAP	150		4

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDC	Dashboard title	SPL version	Validation	Dashboard ZIP
43071-100	MIRAE SKIN (WITCH HAZEL) SOAP [HUMAN AND NATURE]	4	Legacy NDC, 1 package rows	20181219_05f6cca2-5f5f-4538-8def-0c459b5ca4c0.zip

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
Ingredient	Type	UNII	SPL version
WITCH HAZEL	ACTIVE INGREDIENT	101I4J0U34	3
WITCH HAZEL	ACTIVE MOIETY	101I4J0U34	3
ALLANTOIN	INACTIVE INGREDIENT	344S277G0Z	3
ASCORBIC ACID	INACTIVE INGREDIENT	PQ6CK8PD0R	3
KAOLIN	INACTIVE INGREDIENT	24H4NWX5CO	3
LAURIC ACID	INACTIVE INGREDIENT	1160N9NU9U	3
LINOLEIC ACID	INACTIVE INGREDIENT	9KJL21T0QJ	3
MYRISTIC ACID	INACTIVE INGREDIENT	0I3V7S25AW	3
OLEIC ACID	INACTIVE INGREDIENT	2UMI9U37CP	3
PALMITIC ACID	INACTIVE INGREDIENT	2V16EO95H1	3
QUERCETIN	INACTIVE INGREDIENT	9IKM0I5T1E	3
SODIUM HYDROXIDE	INACTIVE INGREDIENT	55X04QC32I	3
WATER	INACTIVE INGREDIENT	059QF0KO0R	3
ZINC OXIDE	INACTIVE INGREDIENT	SOI2LOH54Z	3

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 4 matching rows.

MIRAE SKIN
WITCH HAZEL
WATER
KAOLIN

NDC Codes#

Product NDC, Package NDC table
Product NDC	Package NDC
43071-100	43071-100-01

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 3 matching rows.

Name, UNII, Kind table
Name	UNII	Kind
WITCH HAZEL	101I4J0U34	ACTIB
WATER	059QF0KO0R	IACT
KAOLIN	24H4NWX5CO	IACT

Source Document#

Source XML · Source PDF

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 4 · 234 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredient	IID ingredient	UNII	Dosage form / route	Potency	Maximum daily exposure	Match
SODIUM HYDROXIDE	SODIUM HYDROXIDE	55X04QC32I	INJECTION, POWDER, FOR SOLUTION / INTRATHECAL	ADJ PH		Exact identifier — unii candidate 174 equally ranked IID candidates
SODIUM HYDROXIDE	SODIUM HYDROXIDE	55X04QC32I	INJECTION / INTRABURSAL	ADJ PH		Exact identifier — unii candidate 174 equally ranked IID candidates
SODIUM HYDROXIDE	SODIUM HYDROXIDE	55X04QC32I	SOLUTION / EPIDURAL	ADJ PH		Exact identifier — unii candidate 174 equally ranked IID candidates
SODIUM HYDROXIDE	SODIUM HYDROXIDE	55X04QC32I	SOLUTION / NASAL	20 mg		Exact identifier — unii candidate 174 equally ranked IID candidates
KAOLIN	KAOLIN	24H4NWX5CO	POWDER / TOPICAL		10056 mg	Exact identifier — unii candidate 13 equally ranked IID candidates
SODIUM HYDROXIDE	SODIUM HYDROXIDE	55X04QC32I	TABLET, ORALLY DISINTEGRATING / ORAL		1 mg	Exact identifier — unii candidate 174 equally ranked IID candidates
SODIUM HYDROXIDE	SODIUM HYDROXIDE	55X04QC32I	SPONGE / TOPICAL	ADJ PH		Exact identifier — unii candidate 174 equally ranked IID candidates
SODIUM HYDROXIDE	SODIUM HYDROXIDE	55X04QC32I	FILM / BUCCAL	0.09 mg		Exact identifier — unii candidate 174 equally ranked IID candidates
MYRISTIC ACID	MYRISTIC ACID	0I3V7S25AW	AEROSOL, FOAM / VAGINAL	2 %w/w		Exact identifier — unii candidate 2 equally ranked IID candidates
ALLANTOIN	ALLANTOIN	344S277G0Z	GEL / TOPICAL		8 mg	Exact identifier — unii candidate
SODIUM HYDROXIDE	SODIUM HYDROXIDE	55X04QC32I	INJECTION, POWDER, FOR SOLUTION / INTRADERMAL	ADJ PH		Exact identifier — unii candidate 174 equally ranked IID candidates
SODIUM HYDROXIDE	SODIUM HYDROXIDE	55X04QC32I	GEL / TOPICAL		70 mg	Exact identifier — unii candidate 174 equally ranked IID candidates
ASCORBIC ACID	ASCORBIC ACID	PQ6CK8PD0R	CONCENTRATE / ORAL	6 mg/1ml		Exact identifier — unii candidate 25 equally ranked IID candidates
SODIUM HYDROXIDE	SODIUM HYDROXIDE	55X04QC32I	SOLUTION / RECTAL	NA		Exact identifier — unii candidate 174 equally ranked IID candidates
SODIUM HYDROXIDE	SODIUM HYDROXIDE	55X04QC32I	SHAMPOO / TOPICAL		3 mg	Exact identifier — unii candidate 174 equally ranked IID candidates
SODIUM HYDROXIDE	SODIUM HYDROXIDE	55X04QC32I	INJECTION / INTRATUMOR	ADJ PH		Exact identifier — unii candidate 174 equally ranked IID candidates
OLEIC ACID	OLEIC ACID	2UMI9U37CP	CREAM / TOPICAL	25 %w/w		Exact identifier — unii candidate 11 equally ranked IID candidates
SODIUM HYDROXIDE	SODIUM HYDROXIDE	55X04QC32I	SOLUTION / INTRAOCULAR	ADJ PH		Exact identifier — unii candidate 174 equally ranked IID candidates
SODIUM HYDROXIDE	SODIUM HYDROXIDE	55X04QC32I	SUSPENSION / SUBCUTANEOUS	ADJ PH		Exact identifier — unii candidate 174 equally ranked IID candidates
SODIUM HYDROXIDE	SODIUM HYDROXIDE	55X04QC32I	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRACAVERNOUS	ADJ PH		Exact identifier — unii candidate 174 equally ranked IID candidates
SODIUM HYDROXIDE	SODIUM HYDROXIDE	55X04QC32I	INJECTION / INTRASYNOVIAL	ADJ PH		Exact identifier — unii candidate 174 equally ranked IID candidates
KAOLIN	KAOLIN	24H4NWX5CO	CAPSULE / ORAL	NA		Exact identifier — unii candidate 13 equally ranked IID candidates
SODIUM HYDROXIDE	SODIUM HYDROXIDE	55X04QC32I	INJECTION / SUBCUTANEOUS	31.45 mg		Exact identifier — unii candidate 174 equally ranked IID candidates
KAOLIN	KAOLIN	24H4NWX5CO	CAPSULE, COATED PELLETS / ORAL		234 mg	Exact identifier — unii candidate 13 equally ranked IID candidates
KAOLIN	KAOLIN	24H4NWX5CO	TABLET, SUGAR COATED / ORAL	NA		Exact identifier — unii candidate 13 equally ranked IID candidates
OLEIC ACID	OLEIC ACID	2UMI9U37CP	SOLUTION / TOPICAL	7.4 %w/w		Exact identifier — unii candidate 11 equally ranked IID candidates
SODIUM HYDROXIDE	SODIUM HYDROXIDE	55X04QC32I	AEROSOL, FOAM / TOPICAL	ADJ PH		Exact identifier — unii candidate 174 equally ranked IID candidates
ASCORBIC ACID	ASCORBIC ACID	PQ6CK8PD0R	INJECTION / INTRAVENOUS		1440 mg	Exact identifier — unii candidate 25 equally ranked IID candidates
SODIUM HYDROXIDE	SODIUM HYDROXIDE	55X04QC32I	INJECTION / EXTRACORPOREAL	ADJ PH		Exact identifier — unii candidate 174 equally ranked IID candidates
KAOLIN	KAOLIN	24H4NWX5CO	TABLET, EXTENDED RELEASE / ORAL	66 mg		Exact identifier — unii candidate 13 equally ranked IID candidates
ASCORBIC ACID	ASCORBIC ACID	PQ6CK8PD0R	SOLUTION / TOPICAL	0.04 %w/w		Exact identifier — unii candidate 25 equally ranked IID candidates
SODIUM HYDROXIDE	SODIUM HYDROXIDE	55X04QC32I	INJECTION, POWDER, FOR SUSPENSION / INTRAVENOUS	ADJ PH		Exact identifier — unii candidate 174 equally ranked IID candidates
SODIUM HYDROXIDE	SODIUM HYDROXIDE	55X04QC32I	MOUTHWASH / BUCCAL	2 mg/1ml		Exact identifier — unii candidate 174 equally ranked IID candidates
KAOLIN	KAOLIN	24H4NWX5CO	SYSTEM / TOPICAL		420 mg	Exact identifier — unii candidate 13 equally ranked IID candidates
SODIUM HYDROXIDE	SODIUM HYDROXIDE	55X04QC32I	INJECTION, POWDER, FOR SOLUTION / INTRATUMOR	ADJ PH		Exact identifier — unii candidate 174 equally ranked IID candidates
ASCORBIC ACID	ASCORBIC ACID	PQ6CK8PD0R	TABLET / ORAL		80 mg	Exact identifier — unii candidate 25 equally ranked IID candidates
SODIUM HYDROXIDE	SODIUM HYDROXIDE	55X04QC32I	INJECTION / INTRALESIONAL	ADJ PH		Exact identifier — unii candidate 174 equally ranked IID candidates
SODIUM HYDROXIDE	SODIUM HYDROXIDE	55X04QC32I	TABLET / ORAL		10 mg	Exact identifier — unii candidate 174 equally ranked IID candidates
SODIUM HYDROXIDE	SODIUM HYDROXIDE	55X04QC32I	INJECTION, POWDER, FOR SOLUTION / PARENTERAL	ADJ PH		Exact identifier — unii candidate 174 equally ranked IID candidates
SODIUM HYDROXIDE	SODIUM HYDROXIDE	55X04QC32I	SOLUTION/ DROPS / AURICULAR (OTIC)	ADJ PH		Exact identifier — unii candidate 174 equally ranked IID candidates
SODIUM HYDROXIDE	SODIUM HYDROXIDE	55X04QC32I	TABLET, DELAYED RELEASE / ORAL		4 mg	Exact identifier — unii candidate 174 equally ranked IID candidates
SODIUM HYDROXIDE	SODIUM HYDROXIDE	55X04QC32I	SOLUTION / INTRAVENOUS	2.78 %w/v		Exact identifier — unii candidate 174 equally ranked IID candidates
SODIUM HYDROXIDE	SODIUM HYDROXIDE	55X04QC32I	SUSPENSION / OPHTHALMIC	ADJ PH		Exact identifier — unii candidate 174 equally ranked IID candidates
MYRISTIC ACID	MYRISTIC ACID	0I3V7S25AW	CAPSULE, EXTENDED RELEASE / ORAL		1721 mg	Exact identifier — unii candidate 2 equally ranked IID candidates
ZINC OXIDE	ZINC OXIDE	SOI2LOH54Z	INJECTION, SUSPENSION / SUBCUTANEOUS	NA		Exact identifier — unii candidate 6 equally ranked IID candidates
SODIUM HYDROXIDE	SODIUM HYDROXIDE	55X04QC32I	SPRAY, METERED / NASAL	ADJ PH		Exact identifier — unii candidate 174 equally ranked IID candidates
SODIUM HYDROXIDE	SODIUM HYDROXIDE	55X04QC32I	LIQUID / TOPICAL	ADJ PH		Exact identifier — unii candidate 174 equally ranked IID candidates
SODIUM HYDROXIDE	SODIUM HYDROXIDE	55X04QC32I	INJECTION, SOLUTION / INTRAVENOUS		78 mg	Exact identifier — unii candidate 174 equally ranked IID candidates
SODIUM HYDROXIDE	SODIUM HYDROXIDE	55X04QC32I	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRACAVITARY	ADJ PH		Exact identifier — unii candidate 174 equally ranked IID candidates
SODIUM HYDROXIDE	SODIUM HYDROXIDE	55X04QC32I	INJECTION, SOLUTION / INTRATHECAL	ADJ PH		Exact identifier — unii candidate 174 equally ranked IID candidates
SODIUM HYDROXIDE	SODIUM HYDROXIDE	55X04QC32I	ENEMA / RECTAL	0.44 %v/v		Exact identifier — unii candidate 174 equally ranked IID candidates
SODIUM HYDROXIDE	SODIUM HYDROXIDE	55X04QC32I	INJECTION / RETROBULBAR	ADJ PH		Exact identifier — unii candidate 174 equally ranked IID candidates
SODIUM HYDROXIDE	SODIUM HYDROXIDE	55X04QC32I	LIQUID / ORAL	2 mg/5ml		Exact identifier — unii candidate 174 equally ranked IID candidates
SODIUM HYDROXIDE	SODIUM HYDROXIDE	55X04QC32I	INJECTION, SOLUTION / INTRA-ARTICULAR	ADJ PH		Exact identifier — unii candidate 174 equally ranked IID candidates
SODIUM HYDROXIDE	SODIUM HYDROXIDE	55X04QC32I	INJECTION / INTRAPERITONEAL	ADJ PH		Exact identifier — unii candidate 174 equally ranked IID candidates
SODIUM HYDROXIDE	SODIUM HYDROXIDE	55X04QC32I	SUSPENSION, EXTENDED RELEASE / SUBCUTANEOUS	NA		Exact identifier — unii candidate 174 equally ranked IID candidates
SODIUM HYDROXIDE	SODIUM HYDROXIDE	55X04QC32I	SOLUTION/ DROPS / TOPICAL	ADJ PH		Exact identifier — unii candidate 174 equally ranked IID candidates
SODIUM HYDROXIDE	SODIUM HYDROXIDE	55X04QC32I	SUSPENSION, EXTENDED RELEASE / INTRA-ARTICULAR	ADJ PH		Exact identifier — unii candidate 174 equally ranked IID candidates
SODIUM HYDROXIDE	SODIUM HYDROXIDE	55X04QC32I	INJECTION, SUSPENSION, LIPOSOMAL / INTRAVENOUS	ADJ PH		Exact identifier — unii candidate 174 equally ranked IID candidates
SODIUM HYDROXIDE	SODIUM HYDROXIDE	55X04QC32I	SOLUTION / INTRATHECAL	ADJ PH		Exact identifier — unii candidate 174 equally ranked IID candidates

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
ef1dc4ca-1397-4d61-8ff3-3aad42b9f260			05f6cca2-5f5f-4538-8def-0c459b5ca4c0	2018-12-19	Warnings	Exact identifier spl id: ef1dc4ca-1397-4d61-8ff3-3aad42b9f260 spl set id: 05f6cca2-5f5f-4538-8def-0c459b5ca4c0

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.